Scott L. Friedman, M.D.
Dr. Friedman is professor of medicine and chief of liver diseases at Mount Sinai School of Medicine. He has performed pioneering research into the underlying causes of scarring, or fibrosis, associated with chronic liver disease, which affects millions worldwide. Dr. Friedman was among the first to isolate and characterize the hepatic stellate cell, which is the key cell type responsible for scar production in liver.
Dr. Friedman’s work has been continuously funded by the National Institute of Health since 1985. Dr. Friedman has given invited honorary lectures throughout the world and is also a respected author, with over 200 peer-reviewed publications. Dr. Friedman is a 1979 graduate of Mount Sinai School of Medicine, where he served as the president of Alpha Omega Alpha Honor Society and was an awardee of the Arthur Aufses, Sr. Prize in Surgery. He has served on numerous committees for the American Association for the Study of Liver Diseases (AASLD) and the American Gastroenterological Association (AGA) and is recognized as an AGA Fellow. He is immediate past president of AASLD.
Anatole Klyosov, Ph.D., D.Sc., founder emeritus
Dr. Klyosov, a founder of the company, is a co-inventor of our patented technology. From 1996 to 2000, he was vice president of research and development for Kadant Composites, Inc., a subsidiary of Kadant, Inc. (NYSE:KAI), where he directed a laboratory specializing in biochemistry, microbiology and polymer engineering. From 1990 to 1998, Dr. Klyosov was visiting professor of biochemistry at the Center for Biochemical and Biophysical Sciences at Harvard Medical School. From 1981 to 1990, he was professor and head of the Carbohydrates Research Laboratory at the A.N. Bach Institute of Biochemistry, USSR Academy of Sciences. Dr. Klyosov was elected to the World Academy of Art and Science and is the recipient of distinguished awards including the USSR National Award in Science and Technology. He holds over 20 patents, has published more than 250 peer-reviewed articles in scientific journals, written books on enzymes, carbohydrates and biotechnology, and edited two books, Carbohydrates in Drug Design and Galectins. Dr. Klyosov earned his Ph.D. and D.Sc. degrees in physical chemistry and an M.S. degree in enzyme kinetics from Moscow State University.
Kevin Mayo, Ph.D.
Kevin H Mayo attended Boston University, where he was graduated with an A.B. degree in Chemistry and Biology. He then attended graduate school at the University of Massachusetts, where he received his PhD degree in Chemistry and Biochemistry. Dr. Mayo was then awarded an Alexander von Humboldt Fellowship for post-doctoral research in the lab of Noble Laureate Prof. Rudolf Moessbauer at the Technical University of Munich and the Max Planck Institute for Biochemistry, Germany. Following this, he joined the group of Prof. James Prestegard at Yale University, where he acquired further postdoctoral training in nuclear magnetic resonance (NMR) spectroscopy, before accepting his first academic appointment as Assistant Professor in Chemistry at Temple University, Philadelphia. After having been rapidly promoted to Associate Professor, Dr. Mayo was recruited by Prof. Carlo Croce at the Cancer Center of the Jefferson College of Medicine in Philadelphia to lead their new NMR structural biology and drug discovery initiative.
Currently, Dr. Mayo is Prof. of Biochemistry, Molecular Biology & Biophysics, as well as Lab Medicine & Pathology, at the University of Minnesota, Minneapolis, where he was recruited as a senior faculty member and Director of the High Field NMR Center. He is also a member of the Masonic Cancer Center, the Lillihei Heart Institute for Cardiovascular Research, the Biomedical Engineering Center, and a Senior Fellow of the Supercomputing Institute. Dr. Mayo also serves on the editorial boards of a number of scientific journals and is a member of three US National Institutes of Health research grant review panels, Co-Chair of one of the National American Heart Association Grants Review Committees, and has served on a number of international review panels, including the Deutsche Forschungs Gemeinschaft, Fonds du Recherche Quebec, the European Commission (FP6), the Wellcome Trust, and the Israeli Science Foundation.
Dr. Mayo’s outstanding research in the field of structural biology, drug design and discovery has led to nearly 200 peer-reviewed papers, book chapters, and review articles. His research endeavors have been funded by the US National Institutes of Health, the US National Science Foundation, American Heart Association, American Cancer Society, North Atlantic Treaty Organization, as well as by various private foundations and pharmaceutical companies. Leveraging off of 25 patents on his research findings, Dr. Mayo co-founded the start-up company, PepTx Inc, which presently has one of his compounds in clinical trials as an anti-cancer agent.